Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 August 2025 | Story Martinette Brits | Photo Stephen Collett
Prof Elizabeth Erasmus
Prof Elizabeth Erasmus during her inaugural lecture, Molecules of Change: Chemistry for a Better Tomorrow, on 20 August, highlighting how innovative chemistry can turn waste into value and promote sustainable solutions.

With climate change, resource scarcity, and environmental pollution among the most pressing challenges of our time, Prof Elizabeth (Lizette) Erasmus used her inaugural lecture on Wednesday, 20 August to show how chemistry can provide powerful, practical answers. In her lecture, Molecules of Change: Chemistry for a Better Tomorrow, she traced her journey from fundamental research to pioneering innovations that turn waste into value, protect ecosystems, and improve food security.

During her talk, Prof Erasmus – Researcher in the Department of Chemistry – recalled a moment in 2018 that reshaped her career trajectory. While preparing a Sasol research grant on copper oxide nanoparticles, an entrepreneur assisting with the proposal posed a deceptively simple challenge: “So what?” “Although upsetting at first, those two words completely reshaped my outlook,” she explained. “They inspired my journey from purely academic chemistry towards more applied, impactful research – with the mission of not only advancing science, but of also improving society and the environment.”

 

From fundamental science to global solutions

Prof Erasmus began her career in organometallic chemistry, preparing and characterising complex molecules to understand their reactivity and physical properties. Later, her focus shifted to heterogeneous catalysis, where she explored nanomaterials and surface chemistry.

Her research has since evolved towards developing sustainable technologies that address urgent global challenges. One example is agricultural innovation: using green solvents to extract cellulose from wattle tree bark to create biodegradable superabsorbent polymers. “Unlike the polyacrylates in baby diapers, these SAPs degrade into nutrients for soil microbes and plants,” she explained. “By loading them with fertiliser, we develop slow-release, water-retaining materials that improve agricultural sustainability.”

Other projects include producing biochar to restore degraded soils, creating natural growth enhancers such as wood vinegar, and designing an ‘ultimate fertiliser’ that combines these products for long-term soil health. Her group also works on environmental remediation, developing hydrophobic sponges to absorb oil spills, repurposing building waste to clean polluted water, and using innovative chemistry to convert carbon dioxide into valuable products.

“We are even looking at one of the fastest-growing waste streams: e-waste,” Prof Erasmus noted. “With more gold per ton than natural ore, e-waste represents both a challenge and an opportunity. By developing porous absorbent materials, we can selectively capture and reduce gold ions directly to metallic gold – recovering a precious resource from waste.”

She concluded by crediting her team and collaborators: “This, however, is only the tip of the iceberg. The bulk of the work lies beneath the surface, carried out by dedicated students, collaborators, mentors, colleagues, friends, and family. I owe them my deepest gratitude, for they are the ones who truly sustain this journey of transforming chemistry into solutions for a better world.”

 

About Prof Erasmus

Prof Elizabeth (Lizette) Erasmus obtained all her degrees at the University of the Free State: a BSc (2001), BSc Honours in Chemistry (2002), MSc in Chemistry (2003), and a PhD in Chemistry (2005). She has published more than 80 research papers, holds an H-index of 21, and has extensive experience in supervising MSc and PhD students.

After serving as a senior researcher at the CSIR, she returned to academia at the UFS, where her international collaborations in the Netherlands and at UC Davis broadened her focus from organometallic chemistry to heterogeneous catalysis and nanochemistry. Her expertise spans organometallic chemistry, electrochemistry, surface characterisation, and nanomaterials.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept